LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451

ZHIPENG ZHANG, HONGXI CHEN, YEBIN LU, TIECHENG FENG and WEIJIA SUN

Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China

Received November 10, 2017; Accepted February 13, 2018

DOI: 10.3892/ijo.2018.4289

Abstract. This study examined the effects of long non-coding RNA (lncRNA) BC032020 on the development of human pancreatic ductal adenocarcinoma (PDAC), and the potential molecular mechanisms responsible for these effects. The expression of BC032020 was assessed in 20 pairs of PDAC tumor tissues and adjacent normal tissues. The overexpression of BC032020 was enforced in the AsPC-1 and PANC-1 cells, and the effects on cell proliferation, cell cycle distribution, cell migration and apoptosis were determined. We also analyzed the functions of zinc finger protein 451 (ZNF451), which shares a gene sequence with two exons of BC032020 and a non-coding region with another two exons, in PDAC cells. The AsPC-1 and PANC-1 cells that overexpressed BC032020 were used to establish a subcutaneous tumor xenograft model in order to examine the effects of BC032020 on tumor growth in vivo. The results revealed that the BC032020 levels in the PDAC tumor tissues were lower than those in the adjacent normal tissues, and ZNF451 expression inversely correlated with the BC032020 levels in the PDAC tumor tissues and cell lines. BC032020 overexpression led to a decrease in ZNF451 expression; it also suppressed the proliferation and migration of the AsPC-1 and PANC-1 cells, and induced G1 phase arrest and cell apoptosis. The results of in vivo experiments revealed that BC032020 suppressed tumor growth in a xenograft model by inhibiting ZNF451 expression. Taken together, the findings of this study indicate that BC032020 suppresses the survival of PDAC cells by inhibiting ZNF451 expression.

Introduction

Pancreatic cancer is a very lethal disease with a very poor prognosis, and is the fourth leading cause of cancer-related mortality in the developed world. The standard therapy for patients with metastatic disease has provided only minimal improvements in prognosis, and the incidence and mortality rate associated with pancreatic cancer are almost parallel (1). From a histological viewpoint, almost 95% of pancreatic cancers in humans are pancreatic ductal adenocarcinomas (PDACs), which have the worst prognosis among the major types of cancer (2). The incidence and mortality rates associated with PDAC have remained stable and have not improved over the past three decades. The average lifetime risk of pancreatic cancer for both males and females is 1 in 65 (1.5%), and the 5-year survival rate is 7% (3). As the symptoms of PDAC are difficult to detect at an early stage, the disease is usually diagnosed during its later stages (4,5).

Thus, there is a desperate need for an effective screening program that can detect PDAC and aid in establishing a prognosis during the early stages of the disease. Even though a family history (6,7), cigarette smoking history (7), chronic pancreatitis (8), and diabetes mellitus (9) have been identified as important risk factors for pancreatic cancer, a standard screening protocol is still lacking. When viewed as a genetic disease, pancreatic cancer may be induced by an accumulation of somatic mutations in oncogenes and tumor suppressor genes (10). KRAS, CDKN2A, TP53, and SMAD4 have been identified as major driver genes in PDAC (5,11). The identification of biomarkers that can aid in the prediction and detection of PDAC may prove to be of great clinical significance. Increasing evidence indicates that genetic and modifiable risk factors contribute to the development of PDAC (12,13). As regards genetic conditions, hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, Peutz-Jeghers Syndrome, familial atypical multiple mole melanoma syndrome, hereditary pancreatic cancer, cystic fibrosis and ataxia-telangiectasia have been shown to increase the risk of developing pancreatic cancer (14). As regards modifiable risk factors, tobacco exposure, alcohol use, chronic pancreatitis, diet, obesity and diabetes mellitus, as well as certain abdominal surgeries and infections have also been confirmed as important risk factors for the development of PDAC (15,16).

Long non-coding RNAs (lncRNAs) comprise a group of non-coding RNA molecules that have 200 nt- to 100 kb-long transcripts, and lack an open-reading frame and the capability to code for proteins (17-19). The dysregulation of lncRNAs occurs in numerous diseases, including cancers, and affects tumor development and progression. Numerous studies have indicated that lncRNAs may serve as novel biomarkers for...
the early diagnosis and prognosis of cancer (18,20,21). Even though the function of most lncRNAs remains to be fully elucidated, a number of lncRNAs are now known to act as important regulators in diverse biological processes (22-25). Increasing evidence indicates that lncRNAs are involved in chromosome dosage compensation, epigenetic regulation, nuclear and cytoplasmic trafficking, splicing, transcription, translation, cell cycle control, and cell differentiation (26-28). Furthermore, lncRNAs can regulate the expression of downstream genes by mediating histone modification, chromatin remodeling or serving as precursors for microRNAs (miRNAs) or miRs) or small interfering RNAs (siRNAs) (20).

In pancreatic cancer, some lncRNAs have been shown to play important roles in cell proliferation (29), cell cycle, cell apoptosis (30), cell migration (31), epithelial-mesenchymal transition (32) and drug resistance (33). Although a number of lncRNAs have been found to be dysregulated, little is known about the overall biological functions of lncRNAs in pancreatic cancer. With the avalanche of biological sequences generated in the post-genomic age, much research is required to computationally analyze their structures and functions. Typically, predictors based on machine learning techniques contain three main steps: Feature extraction, predictor construction and performance evaluation. Currently, several web servers and stand-alone tools have been developed to facilitate the biological sequence analysis (34,35).

In this study, we obtained two datasets of lncRNAs in pancreatic cancer tissues from the Cancer RNA-Seq Nexus (CRN) database, and from the intersection of the two datasets we found 13 lncRNAs that were differently expressed in the PDAC tissues when compared with the adjacent non-tumor tissues. Furthermore, we verified that the expression levels of lncRNA BC032020 differed significantly between the two types of tissue (tumor and non-tumor tissue). BC032020 was only slightly expressed in the PDAC tissues and cell lines, and exhibited an inverse correlation with zinc finger protein 451 (ZNF451) expression. The overexpression of BC032020 suppressed cell proliferation and migration, and induced G1 phase arrest and the apoptosis of PDAC cells by inhibiting ZNF451.

Materials and methods

Cell culture and reagents. The PDAC cell lines, AsPC-1 (CRL-1682), BxPC-3 (CRL-1687), PANC-1 (CRL-1469), CFPAC-1 (CRL-1918) and MiaPaCa-2 (CRL-1420) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human pancreatic duct epithelial (HPDE) cells were purchased from Otwo Biotech Inc. (Shenzhen, China). The PDAC cell lines were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The HPDE cells were cultured in M3 medium containing 10% heat-inactivated fetal bovine serum plus epithelial growth factor (EGF), penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA).

Clinical samples. PDAC tumor tissues and adjacent tissues were collected from 20 patients with pancreatic cancer during surgery at Xiangya Hospital (Changsha, China). The details of the patient characteristics were shown in Table I. The collected tumor tissues were identified as PDAC by pathological analysis. The tumor tissues were immediately frozen and stored at -80°C. The protocol for this study was approved by the Institutional Ethics Committee of Xiangya Hospital, and all enrolled patients signed a written informed consent document.

In addition two datasets of lncRNAs in pancreatic cancer tissues datasets (GSE28735 and GSE15471) were obtained from the CRN database (http://syslab4.nchu.edu.tw/CRN).

CCK-8 assay. A Cell Counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan) was used to assess cell proliferation according to the manufacturer's instructions. In brief, aliquots containing 3,000 cells in 100 µl of medium were seeded into the individual wells of a 96-well plate. The cells were then transfected with the indicated plasmids or small interfering RNA (siRNA; pcDNA3.1-Vector, pcDNA3.1-BC032020, pcDNA3.1-ZNF451, si-Control or si-ZNF451; details of the plasmids are provided below) for 24 h; after which, 10 µl of CCK-8 were added to each well. The cells were then further incubated for 1-3 h at 37°C in a water-saturated atmosphere containing 5% CO2. A microplate reader (PerkinElmer, Waltham, MA, USA) was used to detect the absorbance values at 450 nm.

Wound healing assay. Wound healing assays were performed by measuring the movement of cells in a scraped cellular area to assess their motility. The AsPC-1 or PANC-1 cells were seeded onto a 24-well plate at a density of 80-90%. A scratch was then gently and slowly created on the monolayer using a 1 ml pipette tip across the center of the well. After scratching, the wells were gently washed with medium to remove the detached cells and the well was replenished with fresh medium. Wound closure was observed and images were acquired using an optical microscope (Olympus-IX51; Olympus, Tokyo, Japan) to assess the levels of migration after 0 and 48 h, respectively.

Cell cycle analysis. The AsPC-1 and PANC-1 cells were transfected with the plasmids (pcDNA3.1-Vector, pcDNA3.1-BC032020 or pcDNA3.1-ZNF451+ pcDNA3.1-BC032020) or siRNAs (NC siRNA or ZNF451 siRNA) for 12 h, and the cells were then fixed with 80% cold ethanol, and incubated with 0.5% Triton X-100 solution containing 1 mg/ml RNase A at 37°C for 30 min. The cells were then stained with 50 µg/ml propidium iodide (PI; Sigma, St. Louis, MO, USA) for 30 min in the dark. Cell cycle analysis was performed using a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from the PDAC tumor tissues and cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). A 1 µg sample of RNA was used as a template for single strand cDNA synthesis performed using random primers and Primerscript reverse transcriptase (M-MLV, Takara, Shiga, Japan) according to the manufacturer’s instructions. qPCR was performed for GAPDH, BC032020, AX748062, DHRS4-AS1, AK127787 and ZNF451. qPCR was performed as follows: pre-denaturation at 95°C for 10 sec, followed by 40 cycles of denaturation at 95°C for 10 sec and elongation at 60°C for 30 sec. The results were normalized to GAPDH expression. The 2−ΔΔCq method was used for calculating the relative expression levels. The
primers used in this study are listed in Table II. The relative expression levels were detected with an Applied Biosystems step-one plus sequence detection system (Applied Biosystems, Foster City, CA, USA), and fold changes in gene expression were calculated using the $2^{-\Delta\Delta Cq}$ method (36).

**Cell transfection.** Different plasmids (pcDNA3.1-Vector, pcDNA3.1-BC032020 and pcDNA3.1-ZNF451) were created and used to enforce the overexpression of BC0320 and ZNF451 in the AsPC-1 and PANC-1 cells. The BC032020 full-length sequence was synthesized and subcloned into the pCDNA3.1 vector (Invitrogen, Shanghai, China). A siRNA that targets human ZNF451 was used to knockdown ZNF451 expression. The sequence of siRNA used against ZNF451 is shown in Table III. The siRNA was purchased from RiboBio (Guangzhou, China). The cells were transfected with the plasmids or siRNA for 48 h using Lipofectamine 3000 (Invitrogen, Shanghai, China) following the manufacturer's instructions.

**Xenograft model of pancreatic cancer.** All procedures involving animals conformed to the national guidelines of and were approved by the Animal Care Ethics Committee of Xiangya Hospital of Central South University. Male BALB/c nude mice (age, 5-6 weeks; weight, 20-25 g; n=20) were purchased from the Laboratory Animal Center of Shanghai Academy of Science. The mice were randomly divided into 4 groups (AsPC-1-NC, AsPC-BC032020, PANC-1-NC and PANC-1-BC032020; n=5 per group). A human BC032020 lentiviral vector was constructed (GenePharma, Shanghai, China) and used to establish stable BC0320-overexpressing AsPC-1 and PANC-1 cells. Subsequently, $1 \times 10^6$ BC0320-overexpressing AsPC-1 or PANC-1 cells were injected into the right flanks of the BALB/c nude mice. Tumor volumes were measured using a caliper every 3 days, and calculated using the formula, $V = \frac{ab^2}{2}$, where 'a' is the long axis, and 'b' is the short axis. The mice were sacrificed when the mean tumor long axis exceeded 10 mm. The maximum diameter of a single tumor found was 12 mm and no mouse developed multiple tumors. The maximum tumor volume was 672 mm$^3$ in our study. All BALB/c nude mice were sacrificed on the same day (body weight, 30-38 g).

**Hoechst fluorescent staining.** Hoechst fluorescent staining was performed to detect apoptosis at the nuclear stage. In brief, the cells were fixed in ice-cold methanol for 5 min and then incubated with 1 $\mu$g/ml Hoechst 33258 (Life Technologies, Carlsbad, CA, USA) solution for 10 min at room temperature.

### Table I. Patient information.

| Clinical parameter | No. of cases (%) |
|--------------------|------------------|
| Age (years)        |                  |
| ≤55                | 6 (30.0)         |
| >55                | 14 (70.0)        |
| Sex                |                  |
| Male               | 11 (55.0)        |
| Female             | 9 (45.0)         |
| Tumor location     |                  |
| Distal             | 9 (45.0)         |
| Middle             | 4 (20.0)         |
| Proximal           | 7 (35.0)         |
| Tumor size         |                  |
| ≤5 cm              | 14 (70.0)        |
| >5 cm              | 6 (30.0)         |
| TNM stage          |                  |
| I                  | 6 (30.0)         |
| II                 | 8 (40.0)         |
| III                | 4 (20.0)         |
| IV                 | 2 (10.0)         |
| Lymphatic metastasis |              |
| Yes                | 10 (50.0)        |
| No                 | 10 (50.0)        |
| Distant metastasis |                  |
| Yes                | 2 (10.0)         |
| No                 | 18 (90.0)        |

### Table II. Sequences of the primers used for RT-qPCR.

| Name           | Sequence (5’→3’)                      |
|----------------|---------------------------------------|
| H-GAPDH-F      | TGTTCCGTATGGGTGTGAC                    |
| H-GAPDH-R      | ATGGCATGACTGTTGGCAT                   |
| BC032020-F     | CACTGAAGCCTCAACCTCC                   |
| BC032020-R     | ACTTGCTGGAGTGTTGTG                    |
| AX748062-F     | GTTTGGTGCCCAGCCAGTGAAG                |
| AX748062-R     | AGAAGAGTTACGAGTTGCGCTGTAG            |
| DHR54-AS1-F    | GATCCGAGTGCCCTACGC                   |
| DHR54-AS1-R    | GCTCGAATAAAGTGCCG                     |
| AK127787-F     | CTCTGGGGAGATAGACTTTGAG                |
| AK127787-R     | CAGGAAGACTTATGATGTCG                  |

### Table III. The sequence of the siRNA used against zinc finger protein 451 (ZNF451).

| Name       | Sequence (5’→3’)                      |
|------------|---------------------------------------|
| si-ZNF451  | GCAGAATTCAGGACAGCAATTTCAGGCA          |
| siRNA-Control | TGCAGCTGCTGCTGGACACCTATTCT            |
The cells were then washed and examined using a Leica TCS-SP2 confocal microscope (Leica).

**Immunohistochemistry.** The PDAC tumor tissues and adjacent non-tumor tissues were cut at a thickness of 4 µm, after which the sections were fixed in 10% formalin, dehydrated and embedded in paraffin. The slides with the tissue sections were baked, deparaffinized in xylene, passed through a graded alcohol series, and then subjected to antigen retrieval with 1 mM EDTA, pH 8.0 (Invitrogen, Carlsbad, CA, USA). Staining was performed with a primary antibody against ZNF451 (SAB2102880, Sigma) used at a 1:500 dilution. Following immunostaining, the slides were washed and treated with Signal Stain IHC detection reagent (HRP, rabbit; Cell Signaling Technology, Danvers, MA, USA). Areas of tissue staining were developed by incubation with DAB (ab64261) and DAB Enhancer (ab675) (both from Abcam, Cambridge, MA, USA).

**Western blot analysis.** The cells were lysed in ice-cold radio-immunoprecipitation assay buffer (150 mM NaCl, 10 mM Tris, pH 8.0, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS and 5 mM EDTA). The protein extracts from the tumor tissues were prepared by homogenizing the tissues in ice-cold DPBS containing protease and phosphatase inhibitors. Protein concentrations of the collected lysates were measured using a BCA Protein Assay kit (Pierce, Rockford, IL, USA). A 50 µg aliquot of protein from each sample was separated by electrophoresis on a 12% SDS-PAGE gel. The separated protein bands were transferred onto PVDF membranes (Millipore, Billerica, MA, USA) which were then incubated overnight at 4°C with the following primary antibodies specific for ZNF451 (Cat. no. sc-612, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH (Cat. no. SAB2102880; Sigma), p15 (Cat. no. 2946; Cell Signaling Technology), p21 (Cat. no. 5174, Cell Technology), p15 (Cat. no. sc-612, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH (Cat. no. SAB2102880; Sigma). The stained protein bands were then detected using an Alpha Innotech Flour Chem-FC2 imaging system (Alpha Innotech, San Leandro, CA, USA).

**Sequencing analysis.** Sequencing data was illustrated using IGV2.3 software. The following website was used to predict the targets of lncRNA: http://www.herbbol.org:8001/lrt/.

**Statistical analysis.** All results are presented as the means ± SD of values obtained in least 3 independent experiments. The Student's t-test, Mann-Whitney U test, and log-rank test were used to assess differences between 2 groups. For multiple group comparisons ANOVA followed by Tukey's post hoc test was performed. Individual statistics of paired or unpaired samples was performed by paired or unpaired t-test and if not normally distributed by Mann-Whitney test. Karl Pearson's co-efficient of correlation was used to explore the correlation between the expression of BC032020 and ZNF451. A P-value <0.05 was considered to indicate a statistically significant difference.

**Results**

**Decreased expression of BC032020 in pancreatic cancer tissues.** We analyzed two datasets from the CRN database (http://syslab4.nchu.edu.tw/CRN) that listed lncRNAs which exhibited an abnormal expression in patients with pancreatic cancer, and found that 13 lncRNAs were present in both datasets (Table IV). After excluding lncRNAs which had different transcripts in both datasets, we identified 4 lncRNAs that had the same transcript in PDAC tumor tissues and adjacent tissues (Fig. 1). The data indicated that the levels of lncRNAs DHR4-AS1, AK127787 and BC032020 (Fig. 2A) were both increased in the PDAC tumor tissues compared with the adjacent non-tumor tissues, whereas AX748062 (Fig. 1D) was highly expressed in the tumor tissues. As little is known about BC032020 in PDAC and other tumors, we selected BC032020 in order to explore its roles in the development and progression of PDAC.

**Low expression of BC032020 and high expression of ZNF451 in PDAC.** LncRNAs can mediate epigenetic alterations by recruiting chromatin remodeling complexes to specific genomic loci (37). In addition, they can regulate RNA polymerase II activity by interacting with the initiation complex to influence promoter choice (38). Sequence analysis found that ZNF451 shares a gene sequence (456 bp) with two exons of BC032020 and a 3'-non-coding region (234 bp) with another two exons of BC032020 (Fig. 2A), which suggests that an intron sequence or a 3'-non-coding region of ZNF451 is very closely related to the BC032020 sequence, and ZNF451 may thus be a potential gene regulated by BC032020. Subsequently, we found that ZNF451 expression was upregulated in the PDAC tumor tissues when compared with the adjacent non-tumor tissues (Fig. 2B and D). Furthermore, there was an inverse correlation between the levels of BC032020 expression and ZNF451 expression in the specimens of pancreatic cancer tissue (Fig. 2C). We then assessed the levels of BC032020 and ZNF451 expression in the PDAC cells and HPDE cells, and found that the expression levels of BC032020 in the PDAC cells (AsPC-1, BxPC-3, PAN-1, CFPAC-1 and MIA PaCa-2) were lower than those in the HPDE cells (Fig. 2E). The mRNA and protein levels of ZNF451 in the PDAC cells were also significantly increased when compared with the levels in the HPDE cells (Fig. 2F).
and H). Similarly, ZNF451 expression inversely correlated with BC032020 expression in these cell lines (Fig. 2G).

**Overexpression of BC032020 suppresses ZNF451 expression in PDAC cells.** In order to investigate the association between BC032020 and ZNF451, we enforced the overexpression of BC032020 in the AsPC-1 and PANC-1 cells. The transfection efficiency is shown in Fig. 3A. We found that the mRNA levels of ZNF451 in the AsPC-1 and PANC-1 cells were significantly decreased following BC032020 overexpression,
BC032020 overexpression decreases zinc finger protein 451 (ZNF451) expression in pancreatic cancer cells. (A) AsPC-1 and PANC-1 cells were transfected with different plasmids (pcDNA3.1-Vector, pcDNA3.1-BC032020 and pcDNA3.1-ZNF451) to enforce the overexpression of BC032020 or ZNF451. The levels of BC032020 in the pancreatic cancer cells were evaluated by RT-qPCR. Data represent the means ± SD of values obtained from triplicate samples. *P<0.05, **P<0.001. (B) mRNA expression levels of ZNF451 in pancreatic cancer cells were evaluated by RT-qPCR. (C) Immunofluorescence analysis of ZNF451 expression in pancreatic cancer cells (scale bar, 10 µm). (D) Protein levels of ZNF451 in human pancreatic epithelial cells were examined by western blot analysis.

Figure 3. BC032020 overexpression decreases zinc finger protein 451 (ZNF451) expression in pancreatic cancer cells. (A) AsPC-1 and PANC-1 cells were transfected with different plasmids (pcDNA3.1-Vector, pcDNA3.1-BC032020 and pcDNA3.1-ZNF451) to enforce the overexpression of BC032020 or ZNF451. The levels of BC032020 in the pancreatic cancer cells were evaluated by RT-qPCR. Data represent the means ± SD of values obtained from triplicate samples, *P<0.05, **P<0.001. (B) mRNA expression levels of ZNF451 in pancreatic cancer cells were evaluated by RT-qPCR. (C) Immunofluorescence analysis of ZNF451 expression in pancreatic cancer cells (scale bar, 10 µm). (D) Protein levels of ZNF451 in human pancreatic epithelial cells were examined by western blot analysis.
Figure 4. BC032020 suppresses the proliferation and migration, and induces G1 phase arrest and the apoptosis of pancreatic cancer cells. The AsPC-1 and PANC-1 cells were transfected with different plasmids (NC, pcDNA3.1-Vector; BC032020, pcDNA3.1-BC032020; BC032020 + zinc finger protein 451 (ZNF451), pcDNA3.1-BC032020 and pcDNA3.1-ZNF451) to enforce the overexpression of BC032020 or ZNF451. (A) AsPC-1 and PANC-1 cell proliferation was assessed by CCK-8 assay. NC vs. BC032020 (*P<0.05); BC032020 vs. BC032020 + ZNF451 (#P<0.05). (B) The cell cycle distributions of AsPC-1 and PANC-1 cells were detected by flow cytometry. (C) Hoechst staining for AsPC-1 and PANC-1 was performed after 48 h of plasmid transfection (scale bar, 10 µm) (D) Wound healing assay was used to detect cell migration. Data represent the means ± SD of values obtained from triplicate samples.

Figure 5. Zinc finger protein 451 (ZNF451) knockdown suppresses cell proliferation/migration, and induces G1 phase arrest and the apoptosis of pancreatic cancer cells. The AsPC-1 and PANC-1 cells were transfected with small interfering RNA (siRNA; NC, siRNA without any target; si-ZNF451, siRNA targeting ZNF451). (A) The efficiency of ZNF451 knockdown was confirmed by RT-qPCR. NC vs. si-ZNF451, **P<0.001. (B) The proliferation of transfected AsPC-1 and PANC-1 cells was assessed by CCK-8 assay. NC vs. si-ZNF451, *P<0.05. (C) The cell cycle distributions of transfected AsPC-1 and PANC-1 cells were detected by flow cytometry. (D) Hoechst staining foci in AsPC-1 and PANC-1 cells were detected after 48 h of siRNA transfection (scale bar, 10 µm). (E) Wound healing assay was used to detect cell migration. (F) Western blot analyses were performed to detect the protein levels of ZNF451, p15, and p21 in the AsPC-1 and PANC-1 cells. Data represent the means ± SD of results obtained from triplicate samples.
of ZNF451 significantly inhibited the proliferation of both cell lines (Fig. 5B). We also found that ZNF451 knockdown induced G1 phase arrest (Fig. 5C). In addition, greater numbers of apoptotic cells were induced by ZNF451 knockdown when compared with the negative control (NC siRNA) group (Fig. 5D). Moreover, ZNF451 knockdown inhibited the migratory ability of both the AsPC-1 and PANC-1 cells (Fig. 5E). The results from western blot analysis also revealed that the protein levels of p21 and p15 were significantly increased by the silencing of ZNF451 (Fig. 5F). Taken together, our results demonstrated that the silencing of ZNF451 in the AsPC-1 and PANC-1 cells suppressed cell proliferation and migration, but induced G1 phase arrest and apoptosis.

**Discussion**

ZNF451, a poorly characterized vertebrate zinc-finger protein, acts as a transcriptional co-regulator, partially localizing to promyelocytic leukemia bodies (40–42). It is sumoylated itself, and this sumoylation is required for its promyelocytic leukemia body localization. As products of the promyelocytic leukemia gene, promyelocytic leukemia bodies are stress-responsive nuclear structures which are involved in cell differentiation, cell senescence, cell apoptosis, immune responses, and DNA repair (43,44). ZNF451 is a SUMO substrate containing two predicted N-terminal SIMs followed by twelve C2H2 zinc finger domains and an ubiquitin-interacting motif, and interacts with proteins of the SUMOylation machinery (41,42). A number of non-coding RNAs can use RNA-RNA interactions to target specific pre-mRNAs, and achieve their diverse functions (45). IncRNAs can regulate the level of a target gene by mediating histone modification, chromatin remodeling, or acting as an miRNA or small interfering RNA precursor (20). A bioinformatics analysis identified ZNF451...
as a gene potentially regulated by BC032020, which share a gene sequences (456 bp) with two exons of BC032020 and a 3'-non-coding region (234 bp) with another two exons of BC032020. The present study also confirmed that ZNF451 has an inverse correlation with BC032020 expression in PDAC cell lines and pancreatic cancer samples. However, the specific mechanisms underlying the regulation of ZNF451 expression by BC032020 warrant further investigation.

To investigate the association between BC032020 and ZNF451, we enforced the overexpression of BC032020 in the AsPC-1 and Panc-1 cells. We found that BC032020 overexpression decreased the levels of ZNF451 expression in the pancreatic cancer cells. ZNF451 knockdown has been reported to enhance TGF-β-induced p15 and p21 expression, and lead to growth arrest in HaCaT cells (39). Our analysis also revealed that BC032020 overexpression enhanced the levels of p15 and p21. ZNF451 has been described as a Smad3/4-binding protein, and has been reported to inhibit TGF-β-induced cell growth inhibition. The overexpression of ZNF451 has been shown to attenuate TGF-β-induced growth inhibition and gene transcription responses (39). In HaCaT cells, p15 and p21 mRNA and protein levels induced by TGF-β were enhanced by ZNF451 knockdown (39). In this study, BC032020 overexpression enhanced the protein levels of p15 and p21 in pancreatic cancer cells. Furthermore, ZNF451 knockdown also enhanced p15 and p21 expression, while the overexpression of ZNF451 decreased these expression levels.

As a tumor suppressor gene involved in cell cycle regulation, p15 plays an important role in negatively regulating cell proliferation by inhibiting cyclin-dependent kinase 4/6 activity (46-48). A decreased p15 protein expression can lead to retinoblastoma phosphorylation, the subsequent progression of G1/S phase transition, and an acceleration of uncontrolled cell proliferation (49-51). p21 is a potent universal CDK inhibitor that regulates the cell cycle, cell proliferation, senescence and apoptosis (52-56). The lost expression of p21 and p15 mutations is involved in the occurrence of pancreatic cancer (57-60). The p21 protein can prevent Rb phosphorylation by suppressing cyclin D1-CDK4 and cyclin E-CDK2 activity, which leads to cell cycle arrest. The activated tumor suppressor p53 can induce either G1 phase cell cycle arrest or a chronic state of senescence or apoptosis by enhancing the transient expression of p21 (61-64).

In this study, BC032020 overexpression decreased the levels of ZNF451 expression in pancreatic cancer cells, and the knockdown of ZNF451 enhanced the levels of p21 and p15 expression. In view of the roles played by p21 and p15 in cell cycle regulation, cell proliferation, senescence and apoptosis, our data suggest that BC032020 suppresses the proliferation and migration, and induces G1 phase arrest and the apoptosis of pancreatic cancer cells. The results of our in vivo experiments indicated that BC032020 suppressed tumor growth in a xenograft model of pancreatic cancer by inhibiting ZNF451 expression. In conclusion, the findings of the present study BC032020 indicate that suppresses the survival of human PDAC cells by targeting ZNF451.

Acknowledgements

Not applicable.

Funding

This study was supported by grants from the Key Projects of Hunan Province Science and Technology Plan (no. 2016JC2040).

Availability of data and materials

The analyzed datasets generated during the study are available from the corresponding author on reasonable request.

Authors’ contributions

ZZ and HC designed and performed cell culture experiment and interpreted the data. YL and TF performed the clinical and animal experiments and interpreted the data. WS conceived the study and wrote the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

For the use of human samples, the protocol for this study was approved by the Institutional Ethics Committee of Xiangya Hospital of Central South University (Changsha, China) and all enrolled patients signed a written informed consent document. In addition, all procedures involving animals conformed to the national guidelines of and were approved by the Animal Care Ethics Committee of Xiangya Hospital of Central South University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in pancreatic cancer. CA Cancer J Clin 63: 318-348, 2013.
2. Klein AP: Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 13: 66-74, 2013.
3. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 7: e1000267, 2010.
4. Bapat AA, Hostetter G, Von Hoff DD and Han H: Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer 11: 695-707, 2011.
5. Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet 388: 73-85, 2016.
6. Hruban RH, Canto MI, Goggins M, Schulick R and Klein AP: Update on familial pancreatic cancer. Adv Surg 44: 293-311, 2010.
7. Jodice S, Gandini S, Maisonneuve P and Lowenfels AB: Tobacco and the risk of pancreatic cancer: A review and meta-analysis. Langenbecks Arch Surg 393: 535-545, 2008.
8. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P and Pezzilli R: Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 24: 349-358, 2010.
9. Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Bracci PM, Neale RE, Muscat J, Anderson K, Gallinger S, et al: Diabetes, antidiabetic medications, and pancreatic cancer risk: An analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol 25: 2065-2072, 2014.
57. Kis A, Tatar TZ, Gall T, et al: Frequency of genetic and epigenetic alterations of p14ARF and p16INK4A in head and neck cancer in a Hungarian population. Pathology oncology research. POR 20: 923-929, 2014.

58. Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, Kiuchi J, Nishibeppu K, Konishi H, Shiozaki A, et al: Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Sci Rep 7: 5708, 2017.

59. Villarino N, Signaevskaia L, van Niekerk J, Medal R, Kim H, Lahmy R, Scully K, Pinkerton A, Kim SW, Lowy A, et al: A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget 8: 53154-53167, 2017.

60. Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA and Azmi AS: Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. Small GTPases: Jun 22, 2017 (Epub ahead of print).

61. Zubair H, Bhardwaj A, Ahmad A, Srivastava SK, Khan MA, Patel GK, Singh S and Singh AP: Hydroxytyrosol induces apoptosis and cell cycle arrest and suppresses multiple oncogenic signaling pathways in prostate cancer cells. Nutr Cancer 69: 932-942, 2017.

62. He L, Chen Y, Feng J, Sun W, Li S, Ou M and Tang L: Cellular senescence regulated by SWI/SNF complex subunits through p53/p21 and p16/pRB pathway. Int J Biochem Cell Biol 90: 29-37, 2017.

63. Ren J, Nie Y, Ly M, Shen S, Tang R, Xu Y, Hou Y, Zhao S and Wang T: Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17. Cell Mol Immunol 12: 768-776, 2015.

64. Fischer M: Census and evaluation of p53 target genes. Oncogene 36: 3943-3956, 2017.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.